Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences (EVFM) drives innovation in women's reproductive health with its non-hormonal solutions. This page serves as the definitive source for verified company updates, providing stakeholders with timely access to essential developments.
Track FDA milestones, product availability updates, and strategic partnerships shaping the contraceptive technology landscape. Our curated collection includes earnings reports, clinical trial progress, and market expansion announcements directly from Evofem's communications.
Investors will find critical updates on commercialization efforts for Phexxi® and therapeutic pipeline advancements. Analysts can monitor regulatory filings and intellectual property developments that underpin the company's market position.
Bookmark this page for streamlined access to Evofem's latest progress in creating hormone-free health solutions. Check regularly for authoritative updates on initiatives impacting women's healthcare innovation globally.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced its participation in the Medicaid National Drug Rebate Program, effective January 1, 2021. This agreement allows access to Phexxi® (lactic acid, citric acid, and potassium bitartrate) for Medicaid recipients, ensuring equitable contraceptive options for women. Approximately 69.8 million individuals are covered by Medicaid in the U.S., with around 25 million being adult women. The Medicaid Drug Rebate Program aims to reduce costs for outpatient prescription drugs for Medicaid patients, with broad participation from manufacturers.
Evofem Biosciences (NASDAQ: EVFM) announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference on December 21, 2020. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, the first FDA-approved hormone-free contraceptive vaginal gel, and provide updates on the ongoing EVOGUARD Phase 3 trial. This trial evaluates EVO100 in preventing chlamydia and gonorrhea. The presentation will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern on the company's website under the Events and Presentations tab.
Evofem Biosciences (NASDAQ: EVFM) announced progress in its Phase 3 trial, EVOGUARD, evaluating EVO100 for preventing chlamydia and gonorrhea. Launched in October 2020, enrollment exceeded targets amid COVID-19 challenges. Inbound interest from study centers doubled expectations, with one-third operational by year-end. If successful, EVO100 could offer a new preventive method, following the positive AMPREVENCE trial, showing a 50% reduction in chlamydia and 78% for gonorrhea. EVO100 holds Fast Track and QIDP designations from the FDA.
Evofem Biosciences (NASDAQ: EVFM) announced the listing of two U.S. patents for its contraceptive product, Phexxi®, in the FDA's Orange Book. Phexxi, the first FDA-approved non-hormonal vaginal gel for contraception, was approved in May 2020. The listed patents include the '855 patent, which covers contraception methods and expires in March 2033, and the '276 patent, a composition patent expiring in March 2026. CEO Saundra Pelletier highlighted this listing as a crucial step in expanding their patent portfolio and securing the product's market position.
Evofem Biosciences (NASDAQ: EVFM) has secured a five-year contract from the U.S. Department of Veterans Affairs to supply Phexxi®, a hormone-free contraceptive gel, starting December 15, 2020. This contract expands access to Phexxi for approximately 12 million lives, including patients in VA, Tricare, and other government health programs. The company has achieved coverage for 55% of commercial lives in the U.S., with nearly 8 million lives available at zero copay. This milestone marks a significant step in Evofem's mission to broaden access to women's reproductive health solutions.
Evofem Biosciences (NASDAQ: EVFM) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. A pre-recorded fireside chat featuring CEO Saundra Pelletier will be available on November 23 at 10:00 AM Eastern Time. The chat can be accessed on the company's website under the Events and Presentations section. Evofem focuses on women's sexual and reproductive health, with its product, Phexxi®, being the first hormone-free vaginal gel approved in the U.S. for pregnancy prevention.
Evofem Biosciences (NASDAQ: EVFM) will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 4:00 p.m. ET. The presentation can be accessed live and archived via the Evofem website. Evofem focuses on developing innovative products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi™, and is currently evaluating EVO100 in a Phase 3 trial for preventing urogenital infections.
Evofem Biosciences (NASDAQ: EVFM) reported financial results for Q3 2020, marking its first product sales of $0.3 million from the launch of Phexxi, a hormone-free contraceptive gel. Total operating expenses rose to $26.4 million, leading to a net loss of $29.9 million, or $(0.37) per share. The company secured a $25 million strategic investment from Adjuvant Capital to fund ongoing clinical trials and expand market access. Evofem initiated the EVOGUARD Phase 3 trial for EVO100, aimed at preventing chlamydia and gonorrhea infections in women.
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on November 9, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and business highlights. Interested parties can access the live webcast and related presentation on the Company's Investor page. Dial-in numbers for participation include (866) 503-5561 (U.S. toll-free) and (253) 336-2965. A telephone replay will be available shortly after the call through November 12, 2020, using conference ID 2639368.
Evofem Biosciences (NASDAQ: EVFM) will participate in a Virtual Investor KOL Roundtable on October 29, 2020, at 2:00 p.m. ET. CEO Saundra Pelletier and CMO Kelly Culwell will discuss women's reproductive health alongside expert Patricia Cason, RN, MS, FNP-BC. The event will delve into the current birth control landscape and contraceptive counseling. A live webcast will be available, with a replay accessible for three months.
FAQ
What is the current stock price of Evofem Bioscienc (EVFM)?
What is the market cap of Evofem Bioscienc (EVFM)?
